PBC treatment Livdelzi shows benefits for 2.5 years in Phase 3 trial
After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC) saw meaningful reductions in liver…
Marisa Wexler, MS, Senior Science Writer — 
Articles by Marisa Wexler
Bylvay eases itch over long term in PFIC, Alagille syndrome patients
Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and sleep in people with…
Iqirvo to treat PBC approved for public funding in England and Wales
England’s National Institute for Health and Care Excellence (NICE) has recommended that Iqirvo (elafibranor) be covered by the country’s National Health Service (NHS)…
PFIC caused by USP53 usually mild form of liver disease: Study
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of the disease, with most of…
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
Protein in blood may be liver scarring marker in biliary atresia
Higher levels of a protein called amyloid precursor protein (APP) in the blood may be a marker of fibrosis, or liver scarring, in biliary…
Zetomipzomib found safe in Phase 2a trial for autoimmune hepatitis
The safety monitoring committee of a Phase 2a clinical trial testing zetomipzomib in people with autoimmune hepatitis has found no major safety issues with…
Therapy to silence SPTBN1 protein eases liver fat, scarring in mice
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…
Efruxifermin Phase 3 trials now enrolling fatty liver disease patients
Three Phase 3 clinical trials testing Akero Therapeutics‘ experimental injection therapy efruxifermin in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated…
Testing set for AX-0810 in biliary atresia, cholestatic liver diseases
AX-0810, an experimental therapy for biliary atresia and other cholestatic diseases, is expected to enter clinical testing by early next year, according to developer…
